Tag Archives: Duchenne Muscular Dystrophy
Government regulation has inadvertently provided manufacturers that repurpose old orphan drugs with significant market power. Sustainable solutions, whether based in public policy or market strategies, must address this unintended effect.
May 4, 2017
A Better Balance Between Accelerated Access And High-Priced New Drugs: A New Conditional Approval Option
A new form of “conditional approval” could accelerate the approval of new drugs and, at the same time, take at least a small step towards reducing the costs of potentially life-saving drugs.
March 20, 2017
What can we learn from the Food and Drug Administration’s controversial approval of the first drug for Duchenne Muscular Dystrophy (DMD)?
October 25, 2016